Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
25,747
Total Claims
$1.4M
Drug Cost
656
Beneficiaries
$2,196
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-84%
Opioid rate vs peers
0.4% vs 2.5% avg
+95%
Cost per patient vs peers
$2,196 vs $1,128 avg
+61%
Brand preference vs peers
13.5% vs 8.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.4%
Opioid Rate
103
Opioid Claims
$743
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,397 claims · $1.2M
Generic: 21,720 claims · $229K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Glargine,hum.Rec.Anlog | 262 | $127K |
| Dapagliflozin Propanediol | 182 | $121K |
| Empagliflozin | 140 | $100K |
| Apixaban | 169 | $97K |
| Rivaroxaban | 122 | $91K |
| Insulin Nph Hum/Reg Insulin Hm | 196 | $70K |
| Sitagliptin Phos/Metformin Hcl | 73 | $46K |
| Levothyroxine Sodium | 733 | $42K |
| Sitagliptin Phosphate | 43 | $35K |
| Linagliptin | 60 | $34K |
| Insulin Glargine,hum.Rec.Anlog | 70 | $29K |
| Sitagliptin Phos/Metformin Hcl | 56 | $28K |
| Insulin Lispro | 68 | $27K |
| Insulin Regular, Human | 69 | $21K |
| Empaglifloz/Linaglip/Metformin | 30 | $20K |
Prescribing Profile
Patient Profile
72
Avg Age
56%
Female
1.79
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data